

Supplementary Table 1: Clinical and biological characteristics of the AML patients included in the microarray studies.

Affymetrix GeneChip® HG-U133 Plus 2.0 microarrays

Patient #	WT1 status	Sex	Age (years)	[WT1/ABL1] × 10 ⁴		Diagnosis	Cytogenetics	Molecular
				WT1 copies				
1	WT1 low	M		137	AML		NA	NA
2	WT1 low	M	63	76.6	AML		46,XY / 46,XY,9q-	FLT3- CEBPA- MLL-
3	WT1 low	M	30	5	AML		46,XY	FLT3- NPM- CEBPA- MLL-
4	WT1 low	F		168	AML		46,XX	FLT3- NPM+ CEBPA- MLL-
5	WT1 low	F		3	AML		47,XX,+8,t(9;11)[18]/46,XX	FLT3- NPM- CEBPA-
6	WT1 high	F	25	43750	AML		46,XX	FLT3+ NPM+CEBPA - MLL-
7	WT1 high	F	47	6545	AML		46,XX/46,XX,t(8;21)(q22;q22),t(10;19)(q;	FLT3- NPM- CEBPA- MLL-
8	WT1 high	M	28	3750	AML		NA	FLT3- NPM- CEBPA- MLL-
9	WT1 high	M		32432	AML		47,XY,+11,i(11)(q10)[18]/46,XY	FLT3- NPM- CEBPA- MLL+
10	WT1 high	M		25161	AML		46,XY	FLT3- NPM- CEBPA- MLL+
11	WT1 high	M	45	15365	AML		nd	FLT3- NPM- CEBPA- MLL+
12	WT1 high	M		8750	AML		normal	FLT3+ NPM- CEBPA - MLL-
13	WT1 high	M	55	6000	AML		46,XY	FLT3+ NPM+CEBPA - MLL-
14	WT1 high	F		8333	AML		normal	FLT3+ NPM+CEBPA - MLL-

Affymetrix GeneChip® Human Exon 1.0 ST microarrays

Patient #	WT1 status	Sex	Age (years)	[WT1/ABL1] × 10 ⁴		Diagnosis	Cytogenetics	Molecular
				WT1 copies				
1	WT1 low	F	60	23.8	AML		normal	FLT3+ NPM- CEBPA - MLL-
2	WT1 low	F	51	83.3	AML		normal	FLT3- NPM+ CEBPA- MLL-
3	WT1 low	M	67	20	AML		normal	FLT3- NPM- CEBPA- MLL-
4	WT1 high	M		8750	AML		normal	FLT3+ NPM- CEBPA- MLL-
5	WT1 high	F	44	28461	AML		normal	FLT3+ NPM+ CEBPA- MLL-